AI Article Synopsis
- The development of anti-cancer drugs is complicated and often fails at high rates, but can be improved with better pre-clinical testing and patient selection using biomarkers.
- The design of early phase clinical trials is crucial for effectively testing new targeted therapies and making the drug development process more efficient.
- This overview examines current phase I clinical trial concepts, emphasizing the importance of adaptive and model-based designs for combination trials.
Article Abstract
The process of anti-cancer drug development is complex, with high attrition rates. Factors that may optimise this process include well-constructed and relevant pre-clinical testing and use of biomarkers for patient selection. However, the design of early phase clinical trials will probably play a vital role in both the robust clinical investigation of new targeted therapies and in streamlining drug development. In this overview, we assess current concepts in phase I clinical trials, highlighting issues and opportunities to improve their meaningfulness. The particular challenge of how to design combination trials is addressed, with focus on the potential of new adaptive and model-based designs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clon.2017.10.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!